PA Medical News about Dronedarone; atrial fibrillation

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Dronedarone may reduce both hospitalization and cardiovascular mortality in AF patients
The Clinical Advisor, 06/26/09

Ehrlich A - Rhythm control strategies for atrial fibrillation (AF) have not been shown to be generally more beneficial compared with rate control. Most patients with rhythm control will have some amount of intermittent AF that necessitates anticoagulation. The principal benefit is for patients who cannot tolerate the symptoms of AF. A recent randomized trial compared dronedarone (400 mg twice daily) with placebo in 4,628 patients (mean age 72 years) with paroxysmal or persistent AF or flutter. All patients had at least one additional risk factor. At mean follow-up of 21 months, dronedarone was associated with lower rates of hospitalization for any cardiovascular event. Cardiovascular mortality was also lower for the dronedarone group, but the difference in all-cause mortality was not significant. About 30% of patients in each group discontinued treatment due to adverse events. Dronedarone was associated with significantly more bradycardia, QT-interval prolongation, GI problems, and skin-related events.

<< Previous
New hospital payment systems: Comparing medical strategies in The...

Next >>
EUS-guided transmural drainage for peripancreatic fluid...